Cambridge Investment Research Advisors’s First Trust Nasdaq Pharmaceuticals ETF FTXH Stock Holding History

Cambridge Investment Research Advisors’s Portfolio FTXH Stock Details FTXH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$671K	Buy	19,540 +3,924	+25%	+$134K	﹤0.01%	2546
2025 Q4	$514K	Buy	15,616 +343	+2%	+$10.7K	﹤0.01%	2696
2025 Q3	$436K	Sell	15,273 -1,713	-10%	-$46.6K	﹤0.01%	2797
2025 Q2	$435K	Buy	16,986 +419	+3%	+$10.6K	﹤0.01%	2669
2025 Q1	$455K	Buy	16,567 +2,663	+19%	+$73.7K	﹤0.01%	2535
2024 Q4	$375K	Buy	+13,904	New	+$390K	﹤0.01%	2658
2023 Q3	–	Sell	-15,572	Closed	-$408K	–	3185
2023 Q2	$408K	Sell	15,572 -8,151	-34%	-$215K	﹤0.01%	2283
2023 Q1	$619K	Buy	23,723 +5,808	+32%	+$156K	﹤0.01%	1942
2022 Q4	$491K	Buy	+17,915	New	+$477K	﹤0.01%	2027

Other funds holding FTXH

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $74.2B AUM 21.09% 1-Year Est. Return

MIM

Marshall Investment Management Littleton, Colorado $208M AUM 30.96% 1-Year Est. Return

Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return

AIP

Ameritas Investment Partners Lincoln, Nebraska $3.25B AUM 28.52% 1-Year Est. Return

Nilsine Partners Greenwood Village, Colorado $1.28B AUM 27.63% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return

VCM

Vivaldi Capital Management Chicago, Illinois $723M AUM 30.89% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Cambridge Investment Research Advisors's FTXH Position: Q1 2026 in Review

Cambridge Investment Research Advisors increased its First Trust Nasdaq Pharmaceuticals ETF (FTXH) stake by 25% in Q1 2026, buying an estimated $134K and bringing the position to 19,540 shares worth $671K. The position accounts for ﹤0.01% of the portfolio, ranked #2546.

Cambridge Investment Research Advisors first reported a position in FTXH in Q4 2022 and has held it in 9 quarters since. 32 funds tracked by Wall St. Rank hold FTXH as of Q1 2026.

Cambridge Investment Research Advisors held 19,540 shares of First Trust Nasdaq Pharmaceuticals ETF worth $671K as of Q1 2026.
Cambridge Investment Research Advisors bought 3,924 First Trust Nasdaq Pharmaceuticals ETF shares in Q1 2026, an estimated $134K.
First Trust Nasdaq Pharmaceuticals ETF made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q1 2026, its #2546 holding.
Cambridge Investment Research Advisors first reported a position in First Trust Nasdaq Pharmaceuticals ETF in Q4 2022 and has held it in 9 quarters since.
32 funds tracked by Wall St. Rank held First Trust Nasdaq Pharmaceuticals ETF as of Q1 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.